"Salvage Therapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.
| Descriptor ID |
D016879
|
| MeSH Number(s) |
E02.895
|
| Concept/Terms |
Salvage Therapy- Salvage Therapy
- Salvage Treatment
- Salvage Treatments
- Treatment, Salvage
- Treatments, Salvage
- Therapy, Salvage
- Salvage Therapies
- Therapies, Salvage
|
Below are MeSH descriptors whose meaning is more general than "Salvage Therapy".
Below are MeSH descriptors whose meaning is more specific than "Salvage Therapy".
This graph shows the total number of publications written about "Salvage Therapy" by people in this website by year, and whether "Salvage Therapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 2 | 2 |
| 2001 | 1 | 2 | 3 |
| 2002 | 2 | 4 | 6 |
| 2003 | 2 | 2 | 4 |
| 2004 | 2 | 3 | 5 |
| 2005 | 1 | 2 | 3 |
| 2006 | 2 | 1 | 3 |
| 2007 | 0 | 2 | 2 |
| 2008 | 1 | 7 | 8 |
| 2009 | 0 | 2 | 2 |
| 2010 | 4 | 4 | 8 |
| 2011 | 3 | 2 | 5 |
| 2012 | 2 | 1 | 3 |
| 2013 | 6 | 2 | 8 |
| 2014 | 5 | 2 | 7 |
| 2015 | 4 | 3 | 7 |
| 2016 | 7 | 0 | 7 |
| 2017 | 3 | 3 | 6 |
| 2018 | 7 | 8 | 15 |
| 2019 | 6 | 1 | 7 |
| 2020 | 3 | 3 | 6 |
| 2021 | 2 | 1 | 3 |
| 2023 | 0 | 3 | 3 |
| 2024 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Salvage Therapy" by people in Profiles.
-
Early outcomes following local salvage treatment with MRI-assisted low-dose rate brachytherapy (MARS) for MRI-visible postsurgical bed recurrences and focal intraprostatic recurrences. Brachytherapy. 2025 Mar-Apr; 24(2):231-237.
-
Salvage Therapy Efficacy is Modified by Risk Group at Diagnosis in Patients With Relapsed Rhabdomyosarcoma. Pediatr Blood Cancer. 2025 Mar; 72(3):e31477.
-
Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting. Urol Oncol. 2025 Mar; 43(3):135-146.
-
Posttreatment surveillance intensity and overall survival in prostate cancer survivors (AFT-30). JNCI Cancer Spectr. 2024 Nov 01; 8(6).
-
Is extended resection for locally advanced thoracic cancer with cardiopulmonary bypass justified? BMC Surg. 2024 Oct 26; 24(1):334.
-
Doxorubicin, Paclitaxel, and Cisplatin (ATP) for Relapsed/Refractory Germ Cell Tumors. Clin Genitourin Cancer. 2024 Dec; 22(6):102242.
-
Outcomes of relapsed favorable-histology Wilms tumor in non-clinical trial setting. Pediatr Blood Cancer. 2025 Jan; 72(1):e31347.
-
Upfront Management of Blastoid Variant Mantle Cell Lymphoma: Making the Case for 2nd/3rd-Generation Bruton Tyrosine Kinase Inhibitor-Based Therapies. Cancer Med. 2024 Oct; 13(19):e70310.
-
Good Outcomes in Salvage Therapy of Fusariosis in Patients With Leukemia: Is It the Host or the Drug? Clin Infect Dis. 2024 08 16; 79(2):571-572.
-
Considerations in Salvage Laryngectomy Reconstruction-To Flap or Not to Flap. JAMA Otolaryngol Head Neck Surg. 2024 Jun 01; 150(6):499-501.